Evotec SE (0IRF.L)

25,91 +0,48 (+1,88%) Alla chiusura: 06:18PM BST

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 5.067

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D.	Chairman of Management Board & CEO	1,32M	N/D	1968
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	804k	N/D	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/D	1970
Dr. Matthias Evers Ph.D.	Chief Bus. Officer & Member of Management Board	636k	N/D	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	N/D	N/D	1974
Ms. Anja Bosler	Principal Accounting Officer and Sr. VP of Group Accounting	N/D	N/D	N/D
Mr. Volker Braun	Sr. VP and Global Head of Investor Relations & ESG	N/D	N/D	N/D
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/D	N/D	N/D
Gabriele Hansen	Sr. VP & Head of Global Corp. Communications & Marketing	N/D	N/D	N/D
Ms. Monika Conradt	Global Head of HR	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Governance aziendale

L'ISS Governance QualityScore di Evotec SE al 1 settembre 2023 è 5. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.